360 related articles for article (PubMed ID: 17877447)
41. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
42. Current status and future directions of platinum/paclitaxel-based chemotherapy of ovarian cancer.
Markman M
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-24-S11-27. PubMed ID: 9314295
[TBL] [Abstract][Full Text] [Related]
43. Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide.
Kennedy MJ; Donehower RC; Rowinsky EK
Semin Oncol; 1995 Aug; 22(4 Suppl 8):23-7. PubMed ID: 7543700
[TBL] [Abstract][Full Text] [Related]
44. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
[TBL] [Abstract][Full Text] [Related]
45. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.
Hortobagyi GN; Holmes FA; Theriault RL; Rahman Z; Buzdar AU
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-13-S11-19. PubMed ID: 9314293
[TBL] [Abstract][Full Text] [Related]
46. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
Bunn PA
Semin Oncol; 1996 Dec; 23(6 Suppl 16):18-25. PubMed ID: 9007116
[TBL] [Abstract][Full Text] [Related]
47. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
[TBL] [Abstract][Full Text] [Related]
48. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy.
Mugabe C; Hadaschik BA; Kainthan RK; Brooks DE; So AI; Gleave ME; Burt HM
BJU Int; 2009 Apr; 103(7):978-86. PubMed ID: 19007363
[TBL] [Abstract][Full Text] [Related]
49. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
[TBL] [Abstract][Full Text] [Related]
50. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.
Zhou Q; Ching AK; Leung WK; Szeto CY; Ho SM; Chan PK; Yuan YF; Lai PB; Yeo W; Wong N
Int J Oncol; 2011 Mar; 38(3):721-31. PubMed ID: 21240457
[TBL] [Abstract][Full Text] [Related]
51. The current state of adjuvant therapy for breast cancer: focus on paclitaxel.
Hudis CA
Semin Oncol; 1999 Feb; 26(1 Suppl 2):1-5. PubMed ID: 10190778
[TBL] [Abstract][Full Text] [Related]
52. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Belani CP; Aisner J; Hiponia D; Engstrom C
Semin Oncol; 1995 Aug; 22(4 Suppl 9):7-12. PubMed ID: 7544028
[TBL] [Abstract][Full Text] [Related]
53. Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience.
Cagnoni PJ; Shpall EJ; Bearman SI; Matthes S; Ross M; Taffs S; Jones RB
Semin Oncol; 1996 Dec; 23(6 Suppl 15):43-8. PubMed ID: 8996598
[TBL] [Abstract][Full Text] [Related]
54. Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials.
Muggia FM; Vafai D; Natale R; Israel V; Zaretsky S; McRae A; Rogers M; Jeffers S
Semin Oncol; 1995 Aug; 22(4 Suppl 9):63-6. PubMed ID: 7644931
[TBL] [Abstract][Full Text] [Related]
55. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
J Clin Oncol; 1994 Feb; 12(2):241-8. PubMed ID: 7509380
[TBL] [Abstract][Full Text] [Related]
56. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action.
Abal M; Andreu JM; Barasoain I
Curr Cancer Drug Targets; 2003 Jun; 3(3):193-203. PubMed ID: 12769688
[TBL] [Abstract][Full Text] [Related]
57. BMS-184476 Bristol-Myers Squibb.
Ojima I; Geney R
Curr Opin Investig Drugs; 2003 Jun; 4(6):732-6. PubMed ID: 12901233
[TBL] [Abstract][Full Text] [Related]
58. Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer: from advanced disease to adjuvant therapy.
Seidman AD; Hudis CA; Norton L
Semin Oncol; 1995 Aug; 22(4 Suppl 8):3-8. PubMed ID: 7543701
[TBL] [Abstract][Full Text] [Related]
59. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Shepherd FA; Latreille J; Paul K; Eisenhauer E
Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
[TBL] [Abstract][Full Text] [Related]
60. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
